Clene (NASDAQ:CLNN) Major Shareholder Sells $51,624.37 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 7,603 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $6.79, for a total transaction of $51,624.37. Following the sale, the insider owned 419,460 shares of the company’s stock, valued at $2,848,133.40. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The stock was sold at an average price of $7.86, for a total transaction of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total transaction of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The shares were sold at an average price of $6.61, for a total transaction of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The stock was sold at an average price of $6.31, for a total transaction of $44,359.30.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total value of $68,664.20.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The shares were sold at an average price of $6.81, for a total value of $74,276.67.
• On Wednesday, December 10th, Chidozie Ugwumba sold 9,921 shares of Clene stock. The shares were sold at an average price of $6.42, for a total value of $63,692.82.
• On Tuesday, December 9th, Chidozie Ugwumba sold 15,031 shares of Clene stock. The stock was sold at an average price of $5.95, for a total value of $89,434.45.
• On Monday, December 8th, Chidozie Ugwumba sold 21,463 shares of Clene stock. The stock was sold at an average price of $5.70, for a total value of $122,339.10.
• On Friday, December 5th, Chidozie Ugwumba sold 37,235 shares of Clene stock. The shares were sold at an average price of $5.94, for a total value of $221,175.90.

Clene Stock Up 10.6%

Shares of Clene stock opened at $6.68 on Friday. The business has a 50 day moving average of $8.51 and a 200 day moving average of $6.23. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The company has a market cap of $69.00 million, a PE ratio of -1.97 and a beta of 0.79.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, research analysts anticipate that Clene Inc. will post -5.19 earnings per share for the current year.

Clene News Summary

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Sell‑side support remains — several research firms (Benchmark, UBS, D. Boral Capital) continue to carry Buy ratings and elevated targets, which can limit downside and support rebounds. MarketBeat CLNN
• Neutral Sentiment: Institutional activity mixed — some hedge funds increased or initiated positions (e.g., Scoggin Management added shares), meaning a portion of supply is being absorbed by institutions rather than retail. MarketBeat Holdings
• Negative Sentiment: Material insider selling by a major shareholder — Ugwumba disclosed many transactions from Dec. 3–17 totaling roughly ~258k shares sold across multiple days (including a 72,748 share sale on Dec. 4 that was reported as a 12.24% position reduction). Heavy, concentrated selling from a >10% holder puts clear downward pressure and likely explains the intraday weakness. InsiderTrades Article
• Negative Sentiment: Weak recent operating results — the company missed Q3 revenue and EPS expectations (reported -$0.85 vs. consensus -$0.60; revenue essentially immaterial), keeping the story speculative and increasing sensitivity to insider flows. SEC Filing

Hedge Funds Weigh In On Clene

Several large investors have recently made changes to their positions in CLNN. Jones Financial Companies Lllp bought a new stake in shares of Clene in the 3rd quarter worth approximately $29,000. Jane Street Group LLC bought a new position in Clene during the 2nd quarter valued at approximately $47,000. Lunt Capital Management Inc. raised its stake in Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after buying an additional 21,217 shares during the last quarter. Finally, Scoggin Management LP raised its stake in Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after buying an additional 42,750 shares during the last quarter. 23.28% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CLNN has been the subject of several research analyst reports. D. Boral Capital restated a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research report on Tuesday, October 14th. Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Finally, UBS Group restated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).